Title: Septra - FDA prescribing information, side effects and uses
Headings: Septra
Septra
On This Page
Septra Description
Septra - Clinical Pharmacology
Geriatric Pharmacokinetics:
Microbiology:
Susceptibility Testing:
Indications and Usage for Septra
Urinary Tract Infections:
Acute Otitis Media:
Acute Exacerbations of Chronic Bronchitis in Adults:
Travelers' Diarrhea in Adults:
Shigellosis:
Pneumocystis Carinii Pneumonia:
Contraindications
Warnings
Adjunctive Treatment with Leucovorin for Pneumocystis jiroveci pneumonia
Precautions
General
Use in the Elderly:
Use in the Treatment of and Prophylaxis for Pneumocystis carinii Pneumonia in Patients with Acquired Immunodeficiency Syndrome (AIDS):
Information for Patients:
Laboratory Tests:
Drug Interactions:
Drug/Laboratory Test Interactions:
Carcinogenesis, Mutagenesis, Impairment of Fertility:
Pregnancy
Teratogenic Effects:
Nonteratogenic Effects:
Nursing Mothers:
Pediatric Use:
Geriatric Use:
Adverse Reactions
Hematologic:
Allergic:
Gastrointestinal:
Genitourinary:
Metabolic:
Neurologic:
Psychiatric:
Endocrine:
Musculoskeletal:
Respiratory System:
Miscellaneous:
Overdosage
Acute:
Chronic:
Septra Dosage and Administration
Urinary Tract Infections and Shigellosis in Adults and Pediatric Patients and Acute Otitis Media in Pediatric Patients:
Acute Exacerbations of Chronic Bronchitis in Adults:
Travelers' Diarrhea in Adults:
Pneumocystis Carinii Pneumonia:
Treatment:
Prophylaxis:
How is Septra Supplied
REFERENCES
PRINCIPAL DISPLAY PANEL - 100 Tablet Bottle Label
100 Tablets
PRINCIPAL DISPLAY PANEL - 20 Tablet Bottle Label
PRINCIPAL DISPLAY PANEL - 100 Tablet Bottle Label
100 Tablets
PRINCIPAL DISPLAY PANEL - 500 Tablet Bottle Label
Frequently asked questions
More about Septra (sulfamethoxazole / trimethoprim)
Consumer resources
Professional resources
Other brands
Other Formulations
Related treatment guides

Content: Indications and Usage for Septra
To reduce the development of drug-resistant bacteria and maintain the effectiveness of Septra and other antibacterial drugs, Septra should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Urinary Tract Infections: For the treatment of urinary tract infections due to susceptible strains of the following organisms: Escherichia coli, Klebsiella species, Enterobacter species, Morganella morganii, Proteus mirabilis, and Proteus vulgaris. It is recommended that initial episodes